Aridis Pharmaceuticals Inc.

0.0810+0.0018+2.21%Vol 210.85K1Y Perf -91.29%
Nov 30th, 2023 15:19 DELAYED
BID0.00 ASK0.00
Open0.0762 Previous Close0.0793
Pre-Market- After-Market-
 - -  - -%
Target Price
10.50 
Analyst Rating
Strong Buy 1.00
Potential %
12.86K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
1.83 
Earnings Rating
Neutral
Market Cap3.61M 
Earnings Date
20th Nov 2023
Alpha-0.04 Standard Deviation0.32
Beta0.88 

Today's Price Range

0.07350.0879

52W Range

0.05001.75

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
1.12%
1 Month
-10.99%
3 Months
-19.00%
6 Months
-71.56%
1 Year
-91.29%
3 Years
-98.76%
5 Years
-99.24%
10 Years
-

TickerPriceChg.Chg.%
ARDS0.08100.00182.21
AAPL189.910.54000.29
GOOG133.91-2.4900-1.83
MSFT378.73-0.1200-0.03
XOM102.740.40000.39
WFC44.590.81001.85
JNJ154.662.55001.68
FB196.640.99000.51
GE121.802.94002.47
JPM156.081.76001.14
ProfitabilityValueIndustryS&P 500US Markets
-
-3 094.00
-3 058.50
-2 324.00
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-63.67
-2.54
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.33-
Q01 2023--0.22-
Q04 2022--0.27-
Q03 2022-0.01-0.42-4 100.00
Q02 2022-0.06-0.45-650.00
Q01 2022-0.51-0.4413.73
Q04 2021-0.58-0.92-58.62
Q03 2021-0.54-1.94-259.26
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.10-122.73Negative
12/2023 QR-0.02--
12/2023 FY0.07--
12/2024 FY-0.09--
Next Report Date-
Estimated EPS Next Report-0.10
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume210.85K
Shares Outstanding44.57K
Shares Float42.12M
Trades Count40
Dollar Volume17.53K
Avg. Volume109.10K
Avg. Weekly Volume61.42K
Avg. Monthly Volume92.56K
Avg. Quarterly Volume173.32K

Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) stock closed at 0.081 per share at the end of the most recent trading day (a 2.21% change compared to the prior day closing price) with a volume of 210.85K shares and market capitalization of 3.61M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. Aridis Pharmaceuticals Inc. CEO is Vu Truong.

The one-year performance of Aridis Pharmaceuticals Inc. stock is -91.29%, while year-to-date (YTD) performance is -93.14%. ARDS stock has a five-year performance of -99.24%. Its 52-week range is between 0.05 and 1.7458, which gives ARDS stock a 52-week price range ratio of 1.83%

Aridis Pharmaceuticals Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 15.71, a price-to-sale (PS) ratio of 166.17, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -171.67%, a ROC of -770.63% and a ROE of 164.06%. The company’s profit margin is -%, its EBITDA margin is -3 058.50%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aridis Pharmaceuticals Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.10 for the next earnings report. Aridis Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aridis Pharmaceuticals Inc. is Strong Buy (1), with a target price of $10.5, which is +12 863.00% compared to the current price. The earnings rating for Aridis Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aridis Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aridis Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.95, ATR14 : 0.02, CCI20 : 13.64, Chaikin Money Flow : -0.55, MACD : 0.00, Money Flow Index : 77.94, ROC : 18.25, RSI : 51.21, STOCH (14,3) : 58.82, STOCH RSI : 0.57, UO : 29.05, Williams %R : -41.18), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aridis Pharmaceuticals Inc. in the last 12-months were: Eric Patzer (Sold 0 shares of value $0 ), Jafri Hasan (Sold 0 shares of value $0 ), Kurland Fred (Sold 0 shares of value $0 ), Vu Truong (Sold 0 shares of value $0 ), Windham-Bannister Susan (Sold 0 shares of value $0 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Moderate Buy
2.00
Moderate Buy
2.00

Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.

CEO: Vu Truong

Telephone: +1 408 385-1742

Address: 5941 Optical Court, San Jose 95138, CA, US

Number of employees: 32

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

60%40%

Bearish Bullish

58%42%

 

News

Stocktwits